Compare ClearPoint Neuro Inc (CLPT) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Northrop Grumman Corporation — how do they compare? ClearPoint Neuro Inc trades at $14.89 (market cap $454.21M), while Northrop Grumman Corporation trades at $573.91 (market cap $81.78B). The key difference: Northrop Grumman Corporation is far larger — about 180× ClearPoint Neuro Inc's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | NOC | |
|---|---|---|
Market Cap | $454.21M | $81.78B |
Sector | Health | Industrials |
52-Week High | $29.60 | $768.02 |
52-Week Low | $8.66 | $496.02 |
Enterprise Value | $488.79M | $95.77B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Northrop Grumman (NOC) trades at $577.89, up 1.1% today, with a bullish technical signal from moving averages and a record $105 billion backlog supporting fundamentals. Recent Q2 2026 earnings beat expectations, with sales growth of 5% and raised full-year guidance (Seeking Alpha, 2026-07-23). Valuation ratios like P/E of 18.3 and ROE of 26.96% reflect strong profitability, though RSI levels indicate overbought conditions.
The outlook is positive due to defense spending tailwinds and strategic contracts, but risks include margin pressure from specific programs and geopolitical volatility. Analysts maintain a buy consensus with a $598.57 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
